Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)
Akira Sezai(Nihon University), Motomi Shiono(Nihon University), Hiroaki Hata(Nihon University), Kin‐ichi Nakata(Nihon University), Masayoshi Soma(Nihon University), Shunji Osaka(Nihon University), Yusuke Ishii(Nihon University), Hiroko Yaoita(Nihon University)
Cited by 85
Related Papers
Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients (NU-FLASH Trial)
|Circulation Journal|2013|120
Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)
|ESC Heart Failure|2020|109
Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting
|Journal of the American College of Cardiology|2011|108
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
|PLoS Medicine|2020|100
Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial
|Journal of Thoracic and Cardiovascular Surgery|2011|96